August 27, 2014 — Telik Inc., a clinical stage oncology drug development company that merged with MabVax Therapeutics Inc. on July 8, announced it has received a $1.5 million contract for the Phase 2 portion of a small business innovation Research (SBIR) contract from the National Cancer Institute (NCI).
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now